As Women’s History Month highlights both progress and persistent gaps in women’s health research, femtech founders are building solutions in a category shaped by decades of underinvestment and underrepresentation.

That context matters. Women’s health has historically received a small share of healthcare investment, and despite serving half the population, femtech companies still receive a limited portion of venture funding. In environments where capital is constrained and trust must be earned quickly, credible signals of value and safety often become part of the conversation earlier than founders expect.

This blog explains why a deliberate science strategy early on is not just helpful, but essential, especially in women’s health. It also offers founders actionable ways to build credibility, accelerate meaningful partnerships, and ultimately succeed in a category shaped by trust gaps and evidence expectations.

Femtech’s Funding Gap and Credibility Challenges

Femtech is one of the fastest-growing areas of digital health innovation, yet investment patterns still reveal a persistent funding gap relative to the size of the opportunity. Global investment in women’s health technology reached approximately $2.2 billion in 2024, accounting for about 8.5% of total digital health funding, according to recent ecosystem analysis from Galen Growth.

Despite this progress, femtech startups still receive a relatively small share of overall digital health investment. The gap is particularly striking given the scale of unmet need across women’s health, including reproductive health, menopause care, chronic conditions that disproportionately affect women, and mental health.

The opportunity is significant. Research from the World Economic Forum and McKinsey & Company estimates that closing the women’s health gap could unlock $1 trillion in additional global economic impact annually by 2040, underscoring how much innovation potential remains in the category.

For founders navigating this environment, the funding landscape creates a unique dynamic. Investors, clinical partners, and enterprise customers often look for stronger signals of credibility earlier in a company’s lifecycle than in many other technology sectors. That means demonstrating not only a compelling vision, but also early evidence that a product is usable, safe, and capable of delivering meaningful value.

Unlike categories where storytelling and growth projections can carry early traction, femtech founders are frequently asked to show early signals of feasibility, usability, or impact in order to reduce perceived risk and build trust.

Why Scientific Evidence Earns Credibility Faster in Femtech

Scientists and clinicians have long noted that women’s health research has been underprioritized in clinical settings and healthcare innovation. Historically, women were excluded from clinical research for reasons ranging from risk concerns during pregnancy to systemic biases in medical study design. This has led to significant gaps in evidence that femtech products now seek to address through technology.

That means femtech founders are navigating not just a tech validation challenge but a historical credibility gap. In other words, expectations around safety, long-term impact, usability, and evidence often arise earlier in diligence conversations because product claims must confront decades of underrepresentation in research.

User Trust and Long-Term Engagement

App engagement research across digital health shows consistent patterns of high abandonment when perceived value is unclear early. While this research spans multiple categories, work on user discontinuance in femtech suggests that mismatches between expectations and experience, whether usability, data relevance, or professional trust contribute to women stopping use of health apps entirely.

For founders, this underscores a core reality: retention isn’t just a KPI for growth, it is also an early signal of whether the product is delivering value and building trust. In digital health, retention is often one of the earliest indicators of whether a product delivers meaningful value. Investors and partners use early retention data to judge whether a product is resonating with real people in real contexts.

Feasibility and Usability Signals Matter Before Outcomes

A common question founders ask is: Do digital health or femtech startups need clinical trials early on?

In most cases, the answer is no. Early evidence in digital health typically begins with feasibility, usability, and engagement signals that form the foundation of digital health evidence generation.

Traditional clinical research often prioritizes health outcomes, but early evidence in femtech can be more nuanced. Metrics like feasibility, usability, user engagement, and consistent use over the first 30 days are often better predictors of long-term value in digital products, and they are cheaper and faster to obtain than large-scale outcomes data.

A structured science strategy helps founders identify which signals matter most for the decisions they are trying to make at each stage.

Early signals may include: 

• User feedback from structured interviews
• Feasibility and usability observations
• Retention curves or early usage patterns
• Qualitative insights about whether the solutions addresses the problem of focus

As companies grow, evidence can evolve to include:

• Real-world usage or pilot programs
• Structured partner or clinician feedback
• Peer-reviewed studies where appropriate

Rather than following a rigid research ladder, the goal is to generate the right level of evidence to support the next business decision. Research planning should function as a roadmap rather than a post-hoc validation step, guiding design decisions, reducing costly pivots, and supporting faster validation.

This staged approach aligns closely with early scientific strategy frameworks that prioritize learning and decision support over premature rigor.

Partnerships Propel Credibility and Scale

Founders who build credible evidence early find easier access to partnerships that matter: health systems, payers, research institutions, and even established pharmaceutical companies. Such collaborations offer more than money. They bring expertise, real-world feedback loops, and brand credibility that help founders navigate complex clinical and regulatory environments.

For decision makers in healthcare organizations, validated digital solutions reduce uncertainty. Evidence helps partners assess safety, usability, and potential value before integrating new tools into clinical workflows or care programs.

These partnerships create a virtuous cycle: evidence supports adoption, adoption yields rich real-world data, and real-world data strengthens claims for further investment and scale.

For founders, evidence is often what turns partnership conversations from exploratory to actionable.

What Is a Science Strategy for a Femtech Startup?

A science strategy is a structured plan for what evidence to generate, when to generate it, and which decisions that evidence should support.

For early-stage femtech companies, this rarely begins with large clinical trials. Instead, it starts with practical signals that reduce uncertainty about product fit and value, such as:

• Usability studies showing that women can easily use the product in real contexts
• Retention and engagement patterns that indicate sustained value and continued interest
• Qualitative interviews that reveal whether the solution addresses the problem it is intended to solve
• Early pilot studies with clinicians, health systems, or employer partners

These signals do not replace clinical evidence. They create the foundation that makes more rigorous research possible later.

For founders, this approach turns science from a late-stage validation step into a decision-making tool embedded in product development.

Integrating Science Strategy Into Your Product Roadmap

Too many founders think about science as something to do after product-market fit. In femtech, that is often too late. A science strategy should be a filter for decisions day one, helping founders:

• Avoid over-claiming what their product does or will do.
• Understand which evidence types matter for their audience.
• Build trust foundations, not checkboxes.

This means aligning product metrics and research milestones with milestones for funding conversations, partnership outreach, and user growth. It means thinking of evidence not as a cost but as a competitive differentiator that informs design, story, and scaling decisions.

Science Strategy Is a Competitive Advantage in Femtech

Too many founders think about science as something to pursue after product-market fit. In femtech, waiting that long often creates avoidable friction with investors, clinicians, and enterprise partners.

A science strategy helps founders move forward with clarity earlier. It guides what signals to observe, which questions to answer next, and how evidence can inform decisions that help the product evolve.

Done well, this approach does more than support research. It strengthens product decisions, reduces risk in partnerships, and builds the kind of trust that women’s health innovation has historically lacked.

For femtech founders navigating a category shaped by both enormous opportunity and longstanding credibility gaps, science is not simply validation.

It is strategy.